Индуцированная контрастными веществами нефропатия
- Авторы: Миронова ОЮ1
-
Учреждения:
- Институт клинической кардиологии им. А.Л. Мясникова ФГБУ РКНПК Минздрава России
- Выпуск: Том 85, № 6 (2013)
- Страницы: 90-95
- Раздел: Передовая статья
- Статья получена: 10.04.2020
- Статья опубликована: 15.06.2013
- URL: https://ter-arkhiv.ru/0040-3660/article/view/31316
- ID: 31316
Цитировать
Полный текст
Аннотация
Аннотация. С увеличением количества инвазивных вмешательств, проводимых с применением контрастных веществ (КВ), профилактика вызванной ими нефропатии становится все более актуальной. В настоящее время разрабатываются различные методы профилактики индуцированной КВ нефропатии (ИКВН) с применением антиоксидантов, интраренальным введением вазодилататоров, проведением гидратационной терапии в соответствии с точным определением количества полученной по мочевому катетеру выделенной жидкости, а также внедрение в практику менее токсичных содержащих йод КВ. К сожалению, современные рекомендации по профилактике ИКВН соблюдаются клиницистами в недостаточной степени как в России, так и за рубежом. Данный обзор освещает основные звенья патогенеза, факторы риска развития и меры возможной профилактики этой патологии.
Полный текст
Индуцированная контрастными веществами нефропатия. - Аннотация. С увеличением количества инвазивных вмешательств, проводимых с применением контрастных веществ (КВ), профилактика вызванной ими нефропатии становится все более актуальной. В настоящее время разрабатываются различные методы профилактики индуцированной КВ нефропатии (ИКВН) с применением антиоксидантов, интраренальным введением вазодилататоров, проведением гидратационной терапии в соответствии с точным определением количества полученной по мочевому катетеру выделенной жидкости, а также внедрение в практику менее токсичных содержащих йод КВ. К сожалению, современные рекомендации по профилактике ИКВН соблюдаются клиницистами в недостаточной степени как в России, так и за рубежом. Данный обзор освещает основные звенья патогенеза, факторы риска развития и меры возможной профилактики этой патологии.×
Об авторах
О Ю Миронова
Институт клинической кардиологии им. А.Л. Мясникова ФГБУ РКНПК Минздрава России
Список литературы
- Stacul F., vab der Molen A.J., Reimer P. et al., on behalf of the Contrast Media Safety Committee of European Society of Urogental Radiology (ESUR). Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2001; 21: 2527-2541.
- Reddan D., Laville M., Garovic V.D. Contrast-induced nephropathy and its prevention: what do we really know from evidence-based findings? J Nephrol 2009; 22: 333-351.
- Davidson C.J., Hlatky M., Morris K.G. et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med 1989; 110: 119-124.
- McCullough P. A., Sandberg K.R. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003; 4: 53-59.
- Bartholomew B.A., Harjai K.J., Dukkipati S. et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004; 93: 1515-1519.
- Hou S.H., Bushinsky D.A., Wish J.B. et al. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983;74:243-248.
- McCullough P.., Adam A., Becker C.R. et al., on behalf of the CIN Consensus Working Panel. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006; 98 (suppl): 27K-36K.
- Levy E.M., Viscoli C.M., Horwitz R.I. The effect of acute renal failure on mortality: a cohort analysis. JAMA 1996; 275: 1489-1494.
- Hauben M., Norwich J., Shapiro E. et al. Multiple cholesterol emboli syndrome - six cases identified through the spontaneous reporting system. Angiology 1995; 46: 779-784.
- Bonser R.S., Buckels J.A.C., Woodward D.A.K., Bullen B.R. Atheroembolic renal failure after transfemoral aortography: a case report. Vasc Surg 1985; 19: 439-442.
- Vassalotti J.A., Delgado F.A., Whelton A. Atheroembolic renal disease. Am J Ther 1996; 3: 544-549.
- Saklayen M.G., Gupta S., Suryaprasad A., Azmeh W. Incidence of atheroembolic renal failure after coronary angiography - a prospective study. Angiology 1997; 48: 609-613.
- Thadhani R.I., Camargo C.A. Jr, Xavier R.J. et al. Atheroembolic renal failure after invasive procedures: natural history based on 52 histologically proven cases. Medicine (Baltimore) 1995; 74: 350-358.
- Morcos S.K., Thomsen H.S., Webb J.A.W. et al. Contrast-media-induced nephrotoxicity: a consensus report. Eur Radiol 1999; 9: 1602-1613.
- Toprak O. Risk markers for contrast-induced nephropathy. Am J Med Sci 2007; 334: 283-290.
- Bartholomew B.A., Harjai K.J., Dukkipati S. et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004; 93: 1515-1519.
- Brown J.R., DeVries J.T., Piper W.D. et al. Serious renal dysfunction after percutaneous coronary interventions can be predicted. Am Heart J 2008; 155: 260-266.
- McCullough P.A., Wolyn R., Rocher L.L. et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-375.
- Mehran R., Aymong E. D., Nikolsky E. et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393-1399.
- Rihal C.S., Textor S.C., Grill D.E. et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264.
- Expressing the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate with Standardized Serum Creatinine Values. Clin Chem 2007; 53 (4): 766-772.
- Dangas G., Iakovou I., Nikolsky E. et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005; 95: 13-19.
- Glassock R.J., Winearls C. The global burden of chronic kidney disease: how valid are the estimates? Nephron Clin Pract 2008; 10: c39-c47.
- Delanaye P., Cohen E.P. Formula-based estimates of the GFR: equations variable and uncertain. Nephron Clin Pract 2008; 110: c48-c54.
- Parfrey P.S., Griffiths S.M., Barrett B.J. et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. New Engl J Med 1989; 320: 143-149.
- Gruberg L., Mintz G.S., Mehran R. et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000; 36: 1542-1548.
- Marenzi G., Lauri G., Assanelli E. et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004; 44: 1780-1785.
- Morcos S.K. Prevention of contrast media induced nephrotoxicity after angiographic procedures. J Vasc Interv Radiol 2005; 16: 13-23.
- McCullough P.A., Soman S.S. Contrast-induced nephropathy. Crit Care Clin 2005; 21: 261-280.
- Nikolsky E., Mehran R., Lasic Z. et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 2005; 67: 706-713.
- McCarthy C.S., Becker J.A. Multiple myeloma and contrast media. Radiology 1992; 183: 519-521.
- Preda L., Agazzi A., Raimondi S. et al. Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies. Eur Radiol 2011; 21: 63-69.
- Katzberg R.W., Lamba R. Contrast-induced nephropathy after intravenous administration: fact or fiction? Radiol Clin North Am 2009; 47: 789-800.
- Davidson C., Stacul F., McCullough P.A. et al. Contrast medium use. Am J Cardiol 2006; 98: 42K-58K.
- Barrett B.J., Carlisle E.J. Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188: 171-178.
- Aspelin P., Aubry P., Fransson S.G. et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348: 491-499.
- Chalmers N., Jackson R.W. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999; 72: 701-703.
- McCullough P.A., Bertrand M.E., Brinker J.A. et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006; 48: 692-699.
- Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 2005; 68: 2256-2263.
- Anderson J.L., Adams C.D., Antman E.M. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2007; 50: 652-726.
- McCullough P.A. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51: 1419-1428.
- Lindsay J., Apple S., Pinnow E.E. et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003; 59: 338-343.
- Freeman R.V., O'Donnell M., Share D. et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002; 90: 1068-1073.
- Manske C.L., Sprafka J.M., Strony J.T. et al. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89: 615-620.
- Laskey W.K., Jenkins C., Selzer F. et al. NHLBI Dynamic Registry Investigators. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 2007; 50: 584-590.
- Волгина Г.В. Контрастиндуцированная нефропатия. Радиология - практика 2007; 6: 42-53.
- Tumlin J., Stacul F., Adam A. et al. Pathophysiology of Contrast-Induced Nephropathy. Am J Cardiol 2006; 98: 14K-20K.
- McCullough P.A., Adam A., Becker C.R. et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006; 98: 27K-36K.
- Stacul F., Adam A., Becker C.R. et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006; 98: 59K-77K.
- Trivedi H.S., Moore H., Nasr S. et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003; 93: C29-C34.
- Mueller C., Buerkle G., Buettner H.J. et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydratation regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329-336.
- Merten G.J., Burgess W.P., Gray L.V. et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291: 2328-2334.
- Brar S. A randomized controlled trial for the prevention of contrast induced nephropathy with sodium bicarbonate vs. sodium chloride in persons undergoing coronary angiography (the MEENA Trial). Paper presented at: 56th Annual Scientific Session of the American College of Cardiology; March 24-27, 2007; New Orleans, Louisiana.
- Meier P., Ko D.T., Tamura A. et al. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Med 2009; 7: 23.
- Tamura A., Goto Y., Miyamoto K. et al. Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure. Am J Cardiol 2009; 104: 921-925.
- Brigouri C., Colombo A., Airoldi F. et al. N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2004; 44: 762-765.
- Majumdar S.R., Kjellstrand C.M., Tymchak W.J. et al. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis 2009; 54: 602-609.
- Ng T.M., Shurmur S.W., Silver M. et al. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN) Int J Cardiol 2006; 109: 322-328.
- Stone G.W., McCullough P.A., Tumlin J.A. et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290: 2284-2291.
- Attallah N., Yassine L., Musial J. et al. The potential role of statins in nephropathy. Clin Nephrol 2004; 62: 273-278.
- Boscheri A., Weinbrenner C. Botzek B. et al. Failure of ascorbic acid to prevent contrast-induced nephropathy in patients with renal dysfunction. Clin Nephrol 2007; 68: 279-286.
- Briguori C., Airoldi F., D'Andrea D. et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007; 115: 1211-1217.
- Ix J.H., Mc Cullough C.E., Chertow G.M. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 2004; 19: 2747-2753.
- Huber W., Eckel F., Hennig M. et al. Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology 2006; 239: 793-804.
- Jo S. H., Koo B.K., Park J.S. et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin n patients with renal insufficiency undergoing coronary angiography (PROMISS) trial - a randomized controlled study. Am Heart J 2008; 155: 499.e11-499.e8.
- Kelly A.M., Dwamena B., Cronin P. et al. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008; 148: 284-294.
- Khanal S., Attallah N., Smith D.E. et al. Statin therapy reduces contrast-induced nephropathy: an analysis of cotemporary percutaneous interventions. Am J Med 2005; 118: 843-849.
- Patti G., Nusca A., Chello M. et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary interventions. Am J Cardiol 2008; 101: 279-285.
- Spargias K., Adrendes E., Demerouti E. et al. Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography intervention. Circulation 2009; 120: 1793-1799.
- Spargias K., Alexopoulos E., Kyrzopoulos S. et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004; 110: 2837-2842.
- Frank H., Werner D., Lorusso V. et al. Simultaneous hemodyalisis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol 2003; 60: 176-182.
- Fishman E.K., Reddan D. What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography. Acta Radiol 2008; 49: 310-320.
- Дундуа Д.П., Кавтеладзе З.А., Бабунашвили А.М. и др. Контрастиндудированная нефропатия: обзор литературы и предварительные данные клинического исследования. Междунар журн интервенцион кардиоангиол 2007; 4: 52-58.
- Дундуа Д.П., Кавтеладзе З.А., Бабунашвили А.М. и др. Контрастиндуцированная нефропатия: методы профилактики и лечения. Междунар журн интервенцион кардиоангиол 2008; 14: 34-35.
- Rudnick M. R., Goldfarb S., Wexler L. et al. Nephrotoxicity of ionic and non-ionic contrast media in 1196 patients: a randomized trial. Kidney Int 1995; 47: 254-261.
- Reddan D., Fshman E.K. Radiologists' knowledge and perceptions of the impact of contrast-induced nephropathy and its risk factors when performing computed tomography examinations: a survey of European radiologists. Eur J Radiol 2008; 66: 235-245.
Дополнительные файлы
![](/img/style/loading.gif)